Anipamil

Anipamil
Names
	IUPAC name 2-(3-methoxyphenyl)-2-[3-[2-(3-methoxyphenyl)ethyl-methylamino]propyl]tetradecanenitrile
Identifiers
CAS Number	83200-10-6 ;
3D model (JSmol)	Interactive image; Interactive image;
ChEMBL	ChEMBL2104548 ;
ChemSpider	49636 ;
ECHA InfoCard	100.072.899
EC Number	280-213-5;
MeSH	Anipamil
PubChem CID	54966;
UNII	9Y54WZV1CJ ;
	InChI InChI=1S/C34H52N2O2/c1-5-6-7-8-9-10-11-12-13-14-23-34(29-35,31-19-16-21-33(28-31)38-4)24-17-25-36(2)26-22-30-18-15-20-32(27-30)37-3/h15-16,18-21,27-28H,5-14,17,22-26H2,1-4H3 Key: PHFDAOXXIZOUIX-UHFFFAOYSA-N ; InChI=1/C34H52N2O2/c1-5-6-7-8-9-10-11-12-13-14-23-34(29-35,31-19-16-21-33(28-31)38-4)24-17-25-36(2)26-22-30-18-15-20-32(27-30)37-3/h15-16,18-21,27-28H,5-14,17,22-26H2,1-4H3 Key: PHFDAOXXIZOUIX-UHFFFAOYAP;
	SMILES CCCCCCCCCCCCC(CCCN(C)CCC1=CC(OC)=CC=C1)(C#N)C1=CC(OC)=CC=C1; N#CC(c1cc(OC)ccc1)(CCCCCCCCCCCC)CCCN(CCc2cccc(OC)c2)C;
Properties
Chemical formula	C34H52N2O2
Molar mass	520.802 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	verify (what is ?)
	Infobox references

Anipamil is a calcium channel blocker,[1] specifically of the phenylalkylamine type. This type is separate from its more common cousin Dihydropyridine. Anipamil is an analog of the more common drug verapamil, which is the most common type of phenylalkylamine style calcium channel blocker. Anipamil has been shown to be a more effective antiarrhythmic medication[2] than verapamil because it does not cause hypertension as seen in verapamil.[3] It is able to do this by bonding to the myocardium tighter then verapamil.[2]

References

Raddino, Riccardo; Poli, Enzo; Pasini, Evasio; Ferrari, Roberto (1992-09-01). "Effects of the novel calcium channel blocker, anipamil, on the isolated rabbit heart". Naunyn-Schmiedeberg's Archives of Pharmacology. 346 (3): 339–344. doi:10.1007/BF00173549. ISSN 0028-1298. PMID 1383837.
Pugsley, M.K. (1995-08-11). "Effects of anipamil, a long acting analog of verapamil, in pigs subjected to myocardial ischemia". Life Sciences. 57 (12): 1219–1231. doi:10.1016/0024-3205(95)02070-Y.
Lefrandt, J. D.; Heitmann, J.; Sevre, K.; Castellano, M.; Hausberg, M.; Fallon, M.; Fluckiger, L.; Urbigkeit, A.; Rostrup, M. (2001-11-01). "The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study". American Journal of Hypertension. 14 (11 Pt 1): 1083–1089. doi:10.1016/S0895-7061(01)02218-X. ISSN 0895-7061. PMID 11724204.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Raddino, Riccardo; Poli, Enzo; Pasini, Evasio; Ferrari, Roberto (1992-09-01). "Effects of the novel calcium channel blocker, anipamil, on the isolated rabbit heart". Naunyn-Schmiedeberg's Archives of Pharmacology. 346 (3): 339–344. doi:10.1007/BF00173549. ISSN 0028-1298. PMID 1383837.

[:0-2] Pugsley, M.K. (1995-08-11). "Effects of anipamil, a long acting analog of verapamil, in pigs subjected to myocardial ischemia". Life Sciences. 57 (12): 1219–1231. doi:10.1016/0024-3205(95)02070-Y.

[3] Lefrandt, J. D.; Heitmann, J.; Sevre, K.; Castellano, M.; Hausberg, M.; Fallon, M.; Fluckiger, L.; Urbigkeit, A.; Rostrup, M. (2001-11-01). "The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study". American Journal of Hypertension. 14 (11 Pt 1): 1083–1089. doi:10.1016/S0895-7061(01)02218-X. ISSN 0895-7061. PMID 11724204.